-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dr.
Gao Zhenhai, co-founder, president and CEO of NiKang Therapeutics (hereinafter referred to as NKT), gave a keynote speech at the 40th JPMorgan Chase Healthcare Annual Conference, introducing the basic situation of the company to investors
.
R&D pipeline According to Dr.
Gao Zhenhai, NKT's R&D pipeline includes 5 products, of which the most advanced is the HIF-2α inhibitor NKT2152
.
NKT's R&D pipeline, hypoxia-inducible factor-2α (HIF-2α), has been validated as an important target for the treatment of von Hippel-Lindau (VHL) deficiency and clear cell renal cell carcinoma (ccRCC)
.
Belzutifan (MK-6482), the world's first HIF-2α inhibitor, has been approved by the FDA in May 2021 and developed by Merck for the treatment of VHL-related renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma or Pancreatic neuroendocrine tumors (pNETs)
.
According to reports, NKT2152 is highly selective for HIF-2α, and has no anti-HIF-1α/ARNT (HIF-1β) activity.
Preclinical data show that it has excellent PK properties and has shown preliminary results in the ccRCC mouse transplantation model.
Dose-dependent antitumor activity
.
At present, the first patient has been dosed in Phase I/II clinical trials of NKT2152 monotherapy for clear cell renal cell carcinoma (ccRCC)
.
However, NKT's development strategy for NKT2152 is not a single drug but a combination therapy, and has signed cooperative development agreements with Pfizer and AVEO Oncology
.
The collaboration with AVEO Oncology is a combination of NKT2152 and Fotivda (tivozanib) for the treatment of advanced renal clear cell carcinoma (ccRCC), with a Phase II clinical trial scheduled to begin in 2022
.
Fotivda is a next-generation VEGF-TKI inhibitor approved by the FDA for the treatment of relapsed/refractory advanced renal cell carcinoma (RCC)
.
The cooperation with Pfizer is to carry out the combined study of CDK4/6 inhibitor palbociclib and subcutaneously administered PD-1 antibody sasanlimab and NKT2152, respectively
.
According to reports, the Phase II clinical trial of the NKT2152 combination therapy is expected to start in the second half of 2022
.
Another product in development that is about to enter the IND stage is a CDK2 inhibitor
.
In the cyclin-dependent kinase (CDK) family, CDK4/6 has a number of drugs on the market and has become an important target in the tumor field, while there are not many companies involved in the CDK2 field
.
According to reports, the development of CDK2 inhibitors by NKT Company can not only overcome the resistance of CDK4/6 inhibitors, but also have high selectivity for CDK2, without causing CDK1 inhibition to reduce safety risks
.
In addition, the company has licensed the exclusive global development rights of a SHP2 inhibitor NKT2173 (ERAS-601) to Erasca, which is currently conducting Phase I clinical trials for the treatment of advanced solid tumors
.
In the non-oncology field, there is only one product in the company's pipeline, the HIF-2α inhibitor NKT2656, and it is expected to complete the IND application submission in the second half of 2022
.
Financing NiKang Therapeutics was incubated and founded by Cambridge Capital at the end of 2017.
In 2017, the A round of financing reached 10 million US dollars.
In September 2020, it completed a 50 million US dollar round of B financing, and in May 2021, it completed a 200 million US dollar round of C financing
.
Key investors include RTW Investments, Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors, among others
.
At the end of 2021, the company's cash balance totaled $230 million
.
Management Team The management team of the company is as follows.
Co-founder Dr.
Zhenhai Gao serves as president and CEO.
The board of directors includes CBC Group Managing Director Sean Cao and CEO Fu Wei
.
Gao Zhenhai, co-founder, president and CEO of NiKang Therapeutics (hereinafter referred to as NKT), gave a keynote speech at the 40th JPMorgan Chase Healthcare Annual Conference, introducing the basic situation of the company to investors
.
R&D pipeline According to Dr.
Gao Zhenhai, NKT's R&D pipeline includes 5 products, of which the most advanced is the HIF-2α inhibitor NKT2152
.
NKT's R&D pipeline, hypoxia-inducible factor-2α (HIF-2α), has been validated as an important target for the treatment of von Hippel-Lindau (VHL) deficiency and clear cell renal cell carcinoma (ccRCC)
.
Belzutifan (MK-6482), the world's first HIF-2α inhibitor, has been approved by the FDA in May 2021 and developed by Merck for the treatment of VHL-related renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastoma or Pancreatic neuroendocrine tumors (pNETs)
.
According to reports, NKT2152 is highly selective for HIF-2α, and has no anti-HIF-1α/ARNT (HIF-1β) activity.
Preclinical data show that it has excellent PK properties and has shown preliminary results in the ccRCC mouse transplantation model.
Dose-dependent antitumor activity
.
At present, the first patient has been dosed in Phase I/II clinical trials of NKT2152 monotherapy for clear cell renal cell carcinoma (ccRCC)
.
However, NKT's development strategy for NKT2152 is not a single drug but a combination therapy, and has signed cooperative development agreements with Pfizer and AVEO Oncology
.
The collaboration with AVEO Oncology is a combination of NKT2152 and Fotivda (tivozanib) for the treatment of advanced renal clear cell carcinoma (ccRCC), with a Phase II clinical trial scheduled to begin in 2022
.
Fotivda is a next-generation VEGF-TKI inhibitor approved by the FDA for the treatment of relapsed/refractory advanced renal cell carcinoma (RCC)
.
The cooperation with Pfizer is to carry out the combined study of CDK4/6 inhibitor palbociclib and subcutaneously administered PD-1 antibody sasanlimab and NKT2152, respectively
.
According to reports, the Phase II clinical trial of the NKT2152 combination therapy is expected to start in the second half of 2022
.
Another product in development that is about to enter the IND stage is a CDK2 inhibitor
.
In the cyclin-dependent kinase (CDK) family, CDK4/6 has a number of drugs on the market and has become an important target in the tumor field, while there are not many companies involved in the CDK2 field
.
According to reports, the development of CDK2 inhibitors by NKT Company can not only overcome the resistance of CDK4/6 inhibitors, but also have high selectivity for CDK2, without causing CDK1 inhibition to reduce safety risks
.
In addition, the company has licensed the exclusive global development rights of a SHP2 inhibitor NKT2173 (ERAS-601) to Erasca, which is currently conducting Phase I clinical trials for the treatment of advanced solid tumors
.
In the non-oncology field, there is only one product in the company's pipeline, the HIF-2α inhibitor NKT2656, and it is expected to complete the IND application submission in the second half of 2022
.
Financing NiKang Therapeutics was incubated and founded by Cambridge Capital at the end of 2017.
In 2017, the A round of financing reached 10 million US dollars.
In September 2020, it completed a 50 million US dollar round of B financing, and in May 2021, it completed a 200 million US dollar round of C financing
.
Key investors include RTW Investments, Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors, among others
.
At the end of 2021, the company's cash balance totaled $230 million
.
Management Team The management team of the company is as follows.
Co-founder Dr.
Zhenhai Gao serves as president and CEO.
The board of directors includes CBC Group Managing Director Sean Cao and CEO Fu Wei
.
